Inovio Pharmaceuticals, Inc.
INO
$1.34
$0.021.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.00 | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.00 | -- | -- |
| Cost of Revenue | 10.83M | 14.07M | 10.26M | 13.33M | 14.52M |
| Gross Profit | -10.83M | -14.07M | -10.26M | -13.33M | -14.52M |
| SG&A Expenses | 7.80M | 7.88M | 7.22M | 7.88M | 8.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.62M | 21.95M | 17.48M | 21.21M | 23.08M |
| Operating Income | -18.62M | -21.95M | -17.48M | -21.21M | -23.08M |
| Income Before Tax | -6.01M | -19.68M | 3.76M | -45.50M | -23.52M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.01M | -19.68M | 3.76M | -45.50M | -23.52M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.01M | -19.68M | 3.76M | -45.50M | -23.52M |
| EBIT | -18.62M | -21.95M | -17.48M | -21.21M | -23.08M |
| EBITDA | -18.30M | -21.63M | -17.14M | -20.86M | -22.73M |
| EPS Basic | -0.07 | -0.28 | 0.06 | -0.87 | -0.61 |
| Normalized Basic EPS | -0.04 | -0.18 | 0.04 | -0.55 | -0.38 |
| EPS Diluted | -0.07 | -0.28 | 0.06 | -0.87 | -0.61 |
| Normalized Diluted EPS | -0.04 | -0.18 | 0.04 | -0.55 | -0.38 |
| Average Basic Shares Outstanding | 81.62M | 69.10M | 62.03M | 52.17M | 38.83M |
| Average Diluted Shares Outstanding | 81.62M | 69.10M | 62.03M | 52.17M | 38.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |